United European Gastroenterology Conference, UEG Week 2019

ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference
  • First evidence of long-term efficacy of ABX464 in ulcerative colitis
  • Endoscopy at Month 12 was performed in 16 / 19 patients, of whom 12 (75%) achieved clinical remission
  • 78% reduction of total mayo score, 89% reduction of endoscopic subscore and 97% reduction of fecal calprotectin biomarker (normalized)
  • Impressive efficacy seen in 8 weeks induction study previously reported is therefore durable or improving in this study
  • Continued good long-term safety profile
  • Ulcerative colitis Phase 2b and rheumatoid arthritis Phase 2a clinical studies ongoing, Crohn’s disease Phase 2a planned